Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.
University of Trieste, PhD Course in Reproductive and Developmental Sciences, Trieste, Italy.
WIREs Mech Dis. 2021 May;13(3):e1509. doi: 10.1002/wsbm.1509. Epub 2020 Oct 5.
Acute lymphoblastic leukemia (ALL) is the most common pediatric hematological malignancy; notwithstanding the success of ALL therapy, severe adverse drugs effects represent a serious issue in pediatric oncology, because they could be both an additional life threatening condition for ALL patients per se and a reason to therapy delay or discontinuation with important fallouts on final outcome. Cancer treatment-related toxicities have generated a significant need of finding predictive pharmacogenomic markers for the a priori identification of at risk patients. In the era of precision medicine, high throughput genomic screening such as genome wide association studies (GWAS) might provide useful markers to tailor therapy intensity on patients' genetic profile. Furthermore, these findings could be useful in basic research for better understanding the mechanistic and regulatory pathways of the biological functions associated with ALL treatment toxicities. The purpose of this review is to give an overview of high throughput genomic screening of the last 10 years that had investigated the landscape of ALL treatment-associated toxicities. This article is categorized under: Cancer > Genetics/Genomics/Epigenetics.
急性淋巴细胞白血病（ALL）是最常见的儿科血液系统恶性肿瘤；尽管 ALL 的治疗取得了成功，但严重的药物不良反应仍是儿科肿瘤学中的一个严重问题，因为它们不仅会使 ALL 患者面临额外的生命威胁，还会导致治疗延迟或停止，从而对最终结果产生重要影响。癌症治疗相关的毒性作用使得人们迫切需要寻找预测性药物基因组标志物，以便事先识别高危患者。在精准医学时代，高通量基因组筛选，如全基因组关联研究（GWAS），可能为根据患者的遗传特征调整治疗强度提供有用的标志物。此外，这些发现对于基础研究也很有用，可以更好地了解与 ALL 治疗毒性相关的生物学功能的机制和调控途径。本文综述了过去 10 年高通量基因组筛选在 ALL 治疗相关毒性方面的研究进展。本文属于以下分类：癌症>遗传学/基因组学/表观遗传学。
